Articles From: ON Semiconductor Announces High Performance System-in-Package (SiP) Solution for Precision-Sensing in Portable Medical Devices to OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) for Pancreatic Cancer


ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has responded to rapidly-evolving product development demands within the portable medical market by introducing Struix, a semi-customizable System-in-Package (SiP) solution for precision sensing and monitoring in a variety of mobile medical electronics including glucose monitors, heart rate monitors and electrocardiogram analyzers.
Sign-up for ON Semiconductor Announces High Performance System-in-Package (SiP) Solution for Precision-Sensing in Portable Medical Devices investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, is enhancing the charge-coupled device (CCD) image sensor portfolio recently acquired from Truesense Imaging with new technology that improves imaging performance for industrial applications.
Sign-up for ON Semiconductor CCD Image Sensor Delivers Enhanced Performance for Intelligent Traffic, Surveillance, Medical Imaging and Industrial Inspection investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, today announced the completion of its acquisition of Aptina Imaging.
Sign-up for ON Semiconductor Completes Acquisition of Aptina Imaging and Provides Guidance for Third Quarter on Impact of Acquisition of Aptina Imaging investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, is expanding its portfolio of high performance CCD image sensors with its latest device targeted to industrial imaging applications.
Sign-up for ON Semiconductor Expands Options for High-Quality CCD Image Capture investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has introduced the LC898214XC Auto Focus Controller for camera modules in smartphones.
Sign-up for ON Semiconductor Introduces All-in-One Auto Focus Controller for Smartphone Camera Modules investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has announced a new Lithium-ion battery protection controller for smartphones and tablets.
Sign-up for ON Semiconductor Introduces Integrated Lithium-ion Battery Protection Controller for Smartphones and Tablets investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, has added three new current mode, fixed frequency switching regulators to its expansive power management product portfolio.
Sign-up for ON Semiconductor Offers Integrated Switching Regulators to Enable High Efficiency Offline Power Converters for Consumer Applications investment picks
ON Semiconductor Corporation (Nasdaq: ONNN ) For the second quarter of 2014, highlights include: Total revenues of $757.6 million GAAP gross margin of 36.0 percent Non-GAAP gross margin of 36.2 percent GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share of $0.20 ON Semiconductor Corporation (Nasdaq: ONNN ), driving energy efficient innovation, today announced that total revenues in the second quarter of 2014 were $757.6 million, up approximately 7.2 percent compared to the first quarter of 2014.
Sign-up for ON Semiconductor Reports Second Quarter 2014 Results investment picks
ON Semiconductor Corporation (Nasdaq: ONNN ), driving energy efficient innovation, plans to announce its financial results for the second quarter, ending June 27, 2014, after the market closes on Thursday, July 31, 2014.
Sign-up for ON Semiconductor to Announce Second Quarter Financial Results investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, is pleased to announce that its North America manufacturing facilities in Pocatello, Idaho, and Gresham, Oregon, have received a superior security rating in an annual vulnerability assessment by the U.S. Department of Defense, Defense Security Service.
Sign-up for ON Semiconductor’s North American Manufacturing Facilities Awarded Superior Security Rating by U.S. Department of Defense, Defense Security Service investment picks
2014/8/28
ADVISORY, Aug.
Sign-up for Once The Musical to Ring The NASDAQ Stock Market Closing Bell investment picks
2014/7/24
Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, today announced that it has been selected to be part of the highly limited Specialty Pharmacy network of Zydelig (idelalisib) tablets.
Sign-up for Onco360® Named to Zydelig® (Idelalisib) Limited Distribution Network; Zydelig is Available Immediately for Order Through Onco360 investment picks
ORCA™ program includes seven Phase 2 trials in tumor types where patient need is acute, including bladder, lung, pancreas and prostate cancers BOTHELL, Wash.
Sign-up for OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment investment picks
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer investment picks
ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer investment picks
OncoGenex Pharmaceuticals Announces Appointment of John A.
Sign-up for OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer investment picks
OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals Announces Pricing of $24 Million Underwritten Registered Direct Offering investment picks
2014/8/7
Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 investment picks
2014/7/8
CALGARY , July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN ® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section chief at The Ohio State University Comprehensive Cancer Center - Arthur G.
Sign-up for Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study investment picks
2014/6/19
CALGARY , June 19, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated May 9, 2014 were elected as directors at its 2014 Annual Meeting of Shareholders, held on Wednesday June 18 th , 2014.
Sign-up for Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders investment picks
2014/8/7
CALGARY , Aug.
Sign-up for Oncolytics Biotech® Inc. Announces Second Quarter 2014 Results investment picks
REDWOOD CITY, Calif., Aug.
Sign-up for OncoMed Pharmaceuticals Announces Removal of Partial Clinical Hold by the FDA for Vantictumab investment picks
REDWOOD CITY, Calif., Aug.
Sign-up for OncoMed Pharmaceuticals Announces Second Quarter 2014 Financial Results investment picks
REDWOOD CITY, Calif., July 2, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced the issuance of a broad U.S. patent relating to FZD-Fc soluble receptors, including OncoMed's clinical-stage candidate ipafricept (FZD8-Fc, OMP-54F28). The new patent, U.S. Patent No.
Sign-up for OncoMed Pharmaceuticals Granted Broad FZD-Fc Composition-of-Matter and Use Patent in U.S. investment picks
REDWOOD CITY, Calif., July 16, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) , a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's " ALPINE " ( A ntibody therapy in first- L ine P ancreatic cancer I nvestigating anti- N otch E fficacy and safety) clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab (OMP-59R5), being studied for the treatment of pancreatic cancer.
Sign-up for OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) for Pancreatic Cancer investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ON Semiconductor Announces High Performance System-in-Package (SiP) Solution for Precision-Sensing in Portable Medical Devices to OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) for Pancreatic Cancer
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices